RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Outlook Therapeutics Stock

Outlook Therapeutics ROE 2024

Outlook Therapeutics ROE

4.09

Ticker

OTLK

ISIN

US69012T2069

WKN

A2PF3C

In 2024, Outlook Therapeutics's return on equity (ROE) was 4.09, a -154.04% increase from the -7.56 ROE in the previous year.

Outlook Therapeutics Aktienanalyse

What does Outlook Therapeutics do?

Outlook Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for eye diseases. The company was originally established in 2010 under the name Oncobiologics. Initially, the company focused on the development of biosimilar products to improve access and reduce costs of biologics. The goal was to bring cheaper alternatives to the market that were equivalent to approved original products. In 2018, the company decided to shift its focus to the development of ophthalmological therapeutics. Oncobiologics was rebranded as Outlook Therapeutics Inc, and the development of biosimilar products was discontinued. Instead, the company has since been focused on researching and developing eye therapies to provide better treatment options for patients with serious eye diseases. The business model of Outlook Therapeutics Inc is primarily based on the development and marketing of high-quality, patented medications for eye diseases. The company utilizes innovative technologies and research approaches to maximize the effectiveness and safety of its products. It works closely with leading experts and clinicians in the field of ophthalmology to ensure that the therapies meet the needs of patients. One of the key areas of Outlook Therapeutics Inc is the development of therapeutics for wet age-related macular degeneration (AMD). Wet AMD is a progressive degenerative eye disease that can lead to rapid vision deterioration. Currently, there are already various medications on the market for treating this condition. However, Outlook Therapeutics Inc is working on developing new therapeutics that have improved effectiveness, longer duration of action, and fewer side effects than existing medications. Another important area for the company is the development of therapeutics for diabetic macular edema, a disease that can occur in individuals with type 2 diabetes. The company is researching improved treatments for this condition, which can often lead to blindness. Outlook Therapeutics Inc offers a variety of products aimed at improving patients' visual capabilities. In addition to the aforementioned medications, the company also provides medication combinations and drugs with special active ingredients. Through continuous research and development, Outlook Therapeutics Inc constantly expands and optimizes its offerings to meet the needs of patients in the field of eye therapy. Overall, the business model of Outlook Therapeutics Inc is focused on advancing the research and development of new therapies for eye diseases. Through innovative technologies and collaboration with experts in the field of ophthalmology, the company aims to improve the quality of life for patients with severe eye diseases and provide them with better treatment options. Outlook Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Outlook Therapeutics's Return on Equity (ROE)

Outlook Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Outlook Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Outlook Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Outlook Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Outlook Therapeutics stock

What is the ROE (Return on Equity) of Outlook Therapeutics this year?

The ROE of Outlook Therapeutics this year is 4.09 undefined.

How has the Return on Equity (ROE) of Outlook Therapeutics developed compared to the previous year?

The ROE of Outlook Therapeutics has increased by -154.04% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Outlook Therapeutics?

A high ROE indicates that Outlook Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Outlook Therapeutics?

A low ROE can indicate that Outlook Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Outlook Therapeutics affect the company?

A change in ROE (Return on Equity) of Outlook Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Outlook Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Outlook Therapeutics?

Some factors that can influence Outlook Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Outlook Therapeutics pay?

Over the past 12 months, Outlook Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Outlook Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Outlook Therapeutics?

The current dividend yield of Outlook Therapeutics is .

When does Outlook Therapeutics pay dividends?

Outlook Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Outlook Therapeutics?

Outlook Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Outlook Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Outlook Therapeutics located?

Outlook Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Outlook Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Outlook Therapeutics from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Outlook Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Outlook Therapeutics in the year 2023?

In the year 2023, Outlook Therapeutics distributed 0 USD as dividends.

In which currency does Outlook Therapeutics pay out the dividend?

The dividends of Outlook Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Outlook Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Outlook Therapeutics

Our stock analysis for Outlook Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Outlook Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.